Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Low Toxicity in Inflammatory Bowel Disease Patients Treated With Abdominal and Pelvic Radiation Therapy.

White EC, Murphy JD, Chang DT, Koong AC.

Am J Clin Oncol. 2015 Dec;38(6):564-9. doi: 10.1097/COC.0000000000000010.

PMID:
24401668
2.

Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.

Goenka A, Magsanoc JM, Pei X, Schechter M, Kollmeier M, Cox B, Scardino PT, Eastham JA, Zelefsky MJ.

Eur Urol. 2011 Dec;60(6):1142-8. doi: 10.1016/j.eururo.2011.08.006. Epub 2011 Aug 12.

PMID:
21855208
3.

Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial.

Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, Bahary JP, Morton GC, Parliament MB, Sandler HM.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):932-8. doi: 10.1016/j.ijrobp.2013.07.041. Epub 2013 Oct 8.

4.

Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer.

Samuelian JM, Callister MD, Ashman JB, Young-Fadok TM, Borad MJ, Gunderson LL.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1981-7. doi: 10.1016/j.ijrobp.2011.01.051. Epub 2011 Apr 7.

PMID:
21477938
5.

Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy.

Ashman JB, Zelefsky MJ, Hunt MS, Leibel SA, Fuks Z.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):765-71.

PMID:
15913914
6.

Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy.

Dolezel M, Odrazka K, Vaculikova M, Vanasek J, Sefrova J, Paluska P, Zouhar M, Jansa J, Macingova Z, Jarosova L, Brodak M, Moravek P, Hartmann I.

Strahlenther Onkol. 2010 Apr;186(4):197-202. doi: 10.1007/s00066-010-2065-x. Epub 2010 Mar 26.

PMID:
20354663
7.

Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques.

Murphy CT, Heller S, Ruth K, Buyyounouski MK, Weinberg D, Uzzo RG, Plimack E, Kutikov A, Chen DY, Horwitz EM.

Pract Radiat Oncol. 2015 May-Jun;5(3):e215-22. doi: 10.1016/j.prro.2014.09.004. Epub 2014 Oct 30.

PMID:
25424586
8.

Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.

Wortel RC, Incrocci L, Pos FJ, Lebesque JV, Witte MG, van der Heide UA, van Herk M, Heemsbergen WD.

Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):737-44. doi: 10.1016/j.ijrobp.2014.12.017.

PMID:
25752386
9.

Comparison of conformal and intensity modulated radiation therapy techniques for treatment of pelvic tumors. Analysis of acute toxicity.

Ferrigno R, Santos A, Martins LC, Weltman E, Chen MJ, Sakuraba R, Lopes CP, Cruz JC.

Radiat Oncol. 2010 Dec 14;5:117. doi: 10.1186/1748-717X-5-117.

10.

Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.

Michalski JM, Purdy JA, Winter K, Roach M 3rd, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, Wilder RB, Hanks GE, Cox JD.

Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):391-402.

PMID:
10661346
11.

Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer.

Minn AY, Hsu A, La T, Kunz P, Fisher GA, Ford JM, Norton JA, Visser B, Goodman KA, Koong AC, Chang DT.

Cancer. 2010 Aug 15;116(16):3943-52. doi: 10.1002/cncr.25246.

12.

Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.

Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI.

Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1124-9. doi: 10.1016/j.ijrobp.2007.11.044.

PMID:
18313526
13.

Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.

Forsythe K, Blacksburg S, Stone N, Stock RG.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):630-5. doi: 10.1016/j.ijrobp.2011.06.2013. Epub 2011 Nov 16.

PMID:
22099032
14.
15.

Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.

McCammon R, Rusthoven KE, Kavanagh B, Newell S, Newman F, Raben D.

Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):413-20. doi: 10.1016/j.ijrobp.2008.10.050. Epub 2009 Apr 11.

PMID:
19362783
16.

Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms.

Willett CG, Ooi CJ, Zietman AL, Menon V, Goldberg S, Sands BE, Podolsky DK.

Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):995-8.

PMID:
10705022
17.

Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.

Deville C, Vapiwala N, Hwang WT, Lin H, Ad VB, Tochner Z, Both S.

Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1389-96. doi: 10.1016/j.ijrobp.2011.04.041. Epub 2011 Jun 12.

PMID:
21664069
18.

Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.

Deville C, Both S, Hwang WT, Tochner Z, Vapiwala N.

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):763-72. doi: 10.1016/j.ijrobp.2009.08.043. Epub 2010 Feb 18.

PMID:
20171807
19.

Short-course, intensity-modulated radiotherapy for localized prostate cancer.

Kupelian PA, Willoughby TR.

Cancer J. 2001 Sep-Oct;7(5):421-6.

PMID:
11693901
20.

Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.

Zelefsky MJ, Wallner KE, Ling CC, Raben A, Hollister T, Wolfe T, Grann A, Gaudin P, Fuks Z, Leibel SA.

J Clin Oncol. 1999 Feb;17(2):517-22.

PMID:
10080594
Items per page

Supplemental Content

Write to the Help Desk